Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$14.08 - $27.63 $372,500 - $730,979
-26,456 Closed
0 $0
Q4 2021

Feb 08, 2022

SELL
$26.55 - $40.57 $1.51 Million - $2.31 Million
-56,864 Reduced 68.25%
26,456 $702,000
Q3 2021

Nov 15, 2021

BUY
$39.27 - $72.94 $647,640 - $1.2 Million
16,492 Added 24.68%
83,320 $3.42 Million
Q2 2021

Aug 16, 2021

SELL
$31.29 - $56.64 $221,783 - $401,464
-7,088 Reduced 9.59%
66,828 $3.79 Million
Q1 2021

May 14, 2021

BUY
$39.71 - $90.58 $1.33 Million - $3.04 Million
33,511 Added 82.94%
73,916 $3.1 Million
Q4 2020

Feb 02, 2021

BUY
$27.07 - $84.35 $256,136 - $798,119
9,462 Added 30.58%
40,405 $2.83 Million
Q3 2020

Nov 05, 2020

BUY
$28.06 - $37.16 $635,699 - $841,859
22,655 Added 273.35%
30,943 $868,000
Q2 2020

Jul 22, 2020

SELL
$18.5 - $34.34 $568,227 - $1.05 Million
-30,715 Reduced 78.75%
8,288 $245,000
Q1 2020

May 06, 2020

BUY
$14.88 - $32.78 $580,364 - $1.28 Million
39,003 New
39,003 $773,000
Q4 2019

Feb 03, 2020

SELL
$19.49 - $32.63 $583,900 - $977,562
-29,959 Closed
0 $0
Q3 2019

Nov 04, 2019

BUY
$22.49 - $26.81 $673,777 - $803,200
29,959 New
29,959 $681,000
Q2 2019

Jul 30, 2019

SELL
$20.48 - $27.76 $333,168 - $451,599
-16,268 Closed
0 $0
Q1 2019

May 09, 2019

SELL
$19.43 - $26.41 $265,996 - $361,552
-13,690 Reduced 45.7%
16,268 $398,000
Q4 2018

Feb 07, 2019

SELL
$18.19 - $31.79 $1.68 Million - $2.94 Million
-92,467 Reduced 75.53%
29,958 $682,000
Q3 2018

Oct 25, 2018

BUY
$27.65 - $38.39 $790,679 - $1.1 Million
28,596 Added 30.48%
122,425 $3.9 Million
Q2 2018

Aug 02, 2018

BUY
$31.4 - $41.01 $2.95 Million - $3.85 Million
93,829 New
93,829 $3.36 Million

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $168M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.